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Pneumonia and pneumococcal disease cause a large disease burden in resource-con-
strained settings. We pursue an extended cost-effectiveness analysis (ECEA) of two fully
publicly financed interventions in Ethiopia: pneumococcal vaccination for newborns and
pneumonia treatment for under-five children in Ethiopia.
Methods
We apply ECEA methods and estimate the program impact on: (1) government program
costs; (2) pneumonia and pneumococcal deaths averted; (3) household expenses related
to pneumonia/pneumococcal disease treatment averted; (4) prevention of household medi-
cal impoverishment measured by an imputed money-metric value of financial risk protec-
tion; and (5) distributional consequences across the wealth strata of the country population.
Available epidemiological and cost data from Ethiopia are applied and the two interventions
are assessed separately at various incremental coverage levels.
Results
Scaling-up pneumococcal vaccines at around 40% coverage would cost about $11.5 million
and avert about 2090 child deaths annually, while a 10% increase of pneumonia treatment
to all children under 5 years of age would cost about $13.9 million and avert 2610 deaths
annually. Health benefits of the two interventions publicly financed would be concentrated
among the bottom income quintile, where 30–40% of all deaths averted would be expected
to occur in the poorest quintile. In sum, the two interventions would eliminate a total of $2.4
million of private household expenditures annually, where the richest quintile benefits from
around 30% of the total private expenditures averted. The financial risk protection benefits
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would be largely concentrated among the bottom income quintile. The results are most sen-
sitive to variations in vaccine price, population size, number of deaths due to pneumonia,
efficacy of interventions and out-of-pocket copayment share.
Conclusions
Vaccine and treatment interventions for children, as shown with the illustrative examples of
pneumococcal vaccine and pneumonia treatment, can bring large health and financial ben-
efits to households in Ethiopia, most particularly among the poorest socio-economic
groups.
Introduction
Globally, 6.6 million children under 5 years of age were estimated to die in 2012 [1]. Lower
respiratory infections are one of the leading causes of death for children under 5, and 10 to
20% [2] of all under-5 deaths have been estimated to be due to pneumonia. Ethiopia is one of
the five countries in the world with most child deaths: 205,000 children under 5 were estimated
to have died in 2012 [1]. As elsewhere, lower respiratory infections are the main killers.
Between 33,000 and 37,000 [3,4] children under 5 die annually from pneumonia in Ethiopia
according to recent estimates. Most of these deaths could easily be averted if effective treatment
and vaccines were available.
Hard priorities need to be made across diseases and population sub-groups in such low-
and middle-income country settings. Little is spent on healthcare in Ethiopia: the total annual
health expenditure is of 18 US$ per capita [5], and information on the opportunity cost of
health care spending are needed [6]. A large proportion of total health spending in Ethiopia is
from out-of-pocket (OOP) expenditures, whose estimates vary between 30 and 40% over the
last ten years [5]. At a policy level, priority decisions must balance trade-offs between maximiz-
ing population health and equalizing the distribution of health outcomes [7–10], including the
prevention of medical impoverishment and the provision of financial risk protection (FRP). A
better understanding on how a broad range of such fairness concerns can empirically be incor-
porated into real world priority decisions is needed [9–11].
Standard cost-effectiveness analysis (CEA) [12] provides important, but incomplete infor-
mation as a basis for priority setting across health interventions and for designing healthcare
packages [6,13]. Information on health inequality among income groups and medical impover-
ishment are important in addition to cost-effectiveness [8,14]. A methodology of extended
cost-effectiveness analysis (ECEA) [15–18] was recently developed to evaluate the conse-
quences of health policy in these domains of equity and FRP, in addition to health improve-
ments, and subsequently applied to the case study of rotavirus vaccination [16]. Rheingans
et al. have estimated income-related mortality differentials from scale-up of rotavirus vaccina-
tion, and found vaccination of populations with low-income to save most lives and to be most
cost-effective [19]. Evaluations of both impact on health and medical impoverishment across
income groups are rare. However, such information is crucial in priority setting, especially in
Ethiopia where close to 40% of the population lives below the income poverty line (less than
1.25 Purchasing Power Parity (PPP) $ per day as defined by the World Bank) [20] and disease
burden is substantial.
Two-thirds of all pneumonia deaths are estimated to be caused by Streptococcus pneumo-
niae,Haemophilus influenzae type B (Hib) and the influenza virus [4]. Only about 30% of all
ECEA of Pneumonia Treatment and Pneumococcal Vaccines in Ethiopia
PLOS ONE | DOI:10.1371/journal.pone.0142691 December 9, 2015 2 / 16
Competing Interests: The authors have declared
that no competing interests exist.
children under the age of 5 with symptoms of pneumonia utilize healthcare in Ethiopia [21].
An ambitious national scale-up of a 13-valent pneumococcal conjugate vaccine (PCV-13), a
three-dose course vaccine, was initiated nationally in 2011 in Ethiopia with support from the
Global Alliance for Vaccines and Immunizations (GAVI) [22]. There is no public information
about the vaccine coverage for this program currently available. Vaccine injections are given at
months 2, 4 and 12 months, respectively. The cost per dose, US$3.50 (as currently procured to
GAVI by manufacturers), has been found to be the main cost-driver in PCV-13 programs, as
in Gambia [23]. GAVI now supports US$3.30 per dose, which leads to a substantial price
reduction for countries like Ethiopia who co-finance only $0.20 per dose [22]. Concurrently,
some health policies in Ethiopia are now also focusing on reducing the burden of pneumonia
deaths by scaling up case management of pneumonia [24].
The objective of this paper is to apply ECEA methods to evaluate scale-up and universal
public finance (UPF)–government financing of an intervention irrespective of who is receiving
it–of pneumococcal vaccine and pneumonia treatment in Ethiopia. With UPF, households
would receive either vaccination or treatment for free at the point of care. More specifically, we
evaluate the magnitude and distribution of expected health outcomes and FRP provided to
individuals in the population by hypothetically increasing coverage of PCV-13 and pneumonia
treatment at various coverage levels.
Methods
We use ECEA methods [15–17] to evaluate the health and non-health impacts of increased
coverage due to UPF of PCV-13 and case management of pneumonia. We hypothetically fol-
low the current under-five birth cohort in Ethiopia. Specifically, we estimate the level and dis-
tribution (across income groups) of the health benefits by the two publicly financed
interventions; the private households’medical expenditures related to treatment of these dis-
eases averted, and the total costs of the program; and the FRP afforded by the program mea-
sured by an imputed money-metric value of insurance provided (see Fig 1 for the conceptual
structure of the ECEA methodology). The two interventions are assessed separately: (I1) PCV-
13 for newborns; (I2) treatment of pneumonia for under-fives. Values for all parameters are
listed and defined in Table 1.
Health benefits
We use estimates of under-5 deaths (U5D) attributed to pneumonia and pneumococcal disease
reported elsewhere [4,25,26]. For all children under 5 years of age in Ethiopia, the following
annual assumptions were applied before scale-up of interventions: 37,000 pneumonia-related
deaths [4,26] and pneumococcal disease cause 12,000 pneumonia deaths (Table 1) [4,26].
There are 90 different serotypes of pneumococci [27]. However, only a fraction of these sero-
types causes invasive disease. Out of all pneumococcal deaths, 90% were due to pneumonia, 7%
to meningitis and 3% to other diseases [28].
Following Rheingans et al. [17], we distributed the total under-five deaths due to pneumonia
and pneumococcal disease in the country, while using a ‘risk index’ varying by different income
groups. Specifically, since pneumonia accounts for a large proportion (around 15%) of under-
five deaths [29], we approximately assumed a risk ratio gradient in dying from pneumonia or






where q5,i is the under-five mortality in wealth group i, as indicated by the Ethiopian
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Demographic Health Survey (EDHS) 2011 [21]. To our knowledge, there are no studies from
sub-Saharan Africa that document the socio-economic gradient of pneumococcal disease bur-
den. The model follows the current birth cohort in Ethiopia and we adjust the ratio Ri by the
percentage of women currently pregnant in each wealth quintile as reported in the EDHS 2011
[21]. Depending on disease-specific mortality, intervention coverage and intervention effec-
tiveness, reductions in disease-specific deaths or cases averted are estimated in each income
group. The approach is static and therefore not able to capture epidemiological changes like
herd immunity and serotype replacement from the vaccine, which could be for example cap-
tured in a dynamic transmission model.
As for the pneumonia treatment base case, there is a 10% incremental increase to the cur-
rent coverage of pneumonia case management across all income groups (Table 1). Average
coverage of pneumonia treatment was 27% before UPF [21]. After UPF, coverage is raised to
37% (on average). Health gains were calculated for the 10% incremental increase. The PCV-13
base case is scaled up from 0% coverage to the Diphteria-Pertussis-Tetanus, 3rd dose (DPT3)
coverage level of the country (38% on average) [21]. DPT3 coverage is meant to reflect a plausi-
ble health system capacity and could be used to estimate the fraction of newborns that would
receive all three doses of PCV-13 in the longer term. Less ambitious and more ambitious cover-
age targets for the two policies are assessed as competing policy options.
PCV-13 protects against the 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F)
that are typically associated with invasive diseases like pneumonia, sepsis and meningitis.
These 13 serotypes have been estimated to cause around 70% of all pneumococcal invasive dis-
ease in GAVI-eligible countries [30]. One meta-analysis of PCV-9 and PCV-11 in African set-
tings found a 26% reduction in all-cause pneumonia-related deaths of children less than five
years of age [31]. The affected fraction of pneumococcal deaths are 33% of all pneumonia
deaths [4]. Drawing on the literature, we assumed a 58% cause-specific mortality reduction
and episode reduction of the vaccine for pneumococcal pneumoniae [32], 64% for pneumococ-
cal meningitis deaths [33], and 89% for non-pneumonia-non-meningitis (NPNM) pneumo-
coccal deaths [34]. Serotype distribution is implied in the vaccine effectiveness. This
assumption is supported by comparing the estimate of PCV-13 efficacy with the cumulative
Fig 1. Summary of the conceptual structure of the methodology of extended cost-effectiveness
analysis (ECEA) where wemeasure the program impact in four domains: (1) health gains; (2)
household private expenditures averted; (3) prevention of household medical impoverishment; and
(4) distributional consequences across the wealth strata of the country population.
doi:10.1371/journal.pone.0142691.g001
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Table 1. Parameters used for the economic evaluation of universal public finance (UPF) for pneumo-
coccal vaccination and pneumonia treatment in Ethiopia.
Parameter Value Reference
Epidemiology
Annual number of births 2,800,000 [53]
Population under 5 years 13,840,000 [54]
Deaths due to pneumonia (U5D, annual) 37,300 [4]
Incidence rate of pneumonia <5 years, all causes 0.07 [21]
Episodes of pneumococci pneumonia annually <5years
(severe)
240,000 (72,300) [26]
Pneumonia-U5D attributed to pneumococci 12,300 [26]
Relative risk ratio of mortality, Q 1–5 1.3; 1.1; 0.9; 0.9; 0.8* [21]




Amoxicillin efficacy as case management of
pneumonia**
0.7 [35]
Vaccine efficacy (per 3-dose course) against:
- Pneumonia deaths/episodes (pneumococcal) 0.58 [32]
- Meningitis deaths (pneumococcal) 0.64 [33]
- NPNM deaths (pneumococcal) 0.89 [34]
Coverage of pneumonia treatment (Q 1–5), before UPF 0.16; 0.25; 0.22; 0.33;
0.62
[21]




Coverage of pneumococcal vaccine (Q 1–5), before
UPF
0; 0; 0; 0; 0 [21]




Probability of outpatient visit due to pneumonia (Q 1–5) 0.16; 0.25; 0.22; 0.33;
0.62
[21]
Probability of inpatient visit due to pneumonia (Q 1–5) 0.09; 0.09; 0.09; 0.09;
0.09
[37]

















Hospitalization cost for Pneumonia (2011 US$) $84 [41]
Hospitalization cost for Meningitis (2011 US$) $182 [41]
Outpatient clinic visit cost for pneumonia (2011 US$) $45 [41]
Cost of transportation to a facility (2011 US$) $7 *** [38]
Vaccine co-finance by Ethiopian government (per dose,
3 doses needed):
- No GAVI subsidy $3.5 [22]
- With GAVI subsidy $0.2 [22]
Vaccination system cost (2011 US$, per 1 vial course, 3
doses needed)
$0.5 [39]
GDP per capita (2011 US$) $360 [5]
(Continued)
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proportion of invasive pneumococcal disorders caused by the PCV-13 serotypes. PCV-13 sero-
types account for around 70% of invasive pneumococcal disorders [30] in most African regions
and PCV-13 efficacy is around 60% for pneumococcal related deaths [32].
The effectiveness of community-based case management of pneumonia draws on a meta-
analysis of studies from Africa, and amoxicillin was found to reduce pneumonia-related deaths
by 70% [35]. In this analysis, antibiotic acts on preventing all kinds of pneumonia deaths, the
pneumococci-related deaths as well those related to other pathogens (e.g. Hib). We used 70%
as effectiveness against all kinds of pneumonia deaths [35]. By case management we mean that
community health workers follow standard clinical algorithms/guidelines [36] to classify respi-
ratory illness and start with oral amoxicillin for mild/moderate cases of pneumonia (fast
breathing and/or chest indrawing) and refer severe cases to health facilities for injectable anti-
biotics and other supportive care.
Consequences for household private expenditures and health systems
Pneumonia and pneumococcal disease, whether fatal or non-fatal, impose an economic and
financial burden on health systems and families and households. Before the introduction of the
program, we assume that individuals privately pay at a 34% level for treatment of pneumonia
(the proportional OOP expenditures on health services in Ethiopia according to estimates by
the World Health Organization (WHO)) [5]. The remaining 66% is covered by the govern-
ment, the demand of which varies by income group. The current coverage of basic vaccines in
Ethiopia is low (S1 Table) [21]. Substantial investments into the routine immunization pro-
gram are needed in order to succeed with high coverage of pneumococcal vaccines. A crude
estimate of introduction costs for strengthening the existing routine immunization program
was therefore done (see S1 Text for details on calculations). Annual government cost of main-
taining current coverage and incremental cost to reach a 90% coverage level for all vaccines
were estimated separately, and then summed up to yield total introduction cost (S1 Table).
We estimate the amount of household private expenditures averted for each income quintile
by UPF of pneumonia treatment and PCV-13. We quantify what households would pay due to
illness-related cost in the absence of the program. Pneumonia-related private expenditures
depend on the incidence and probability of seeking care of severe and less severe cases of all-
cause pneumonia and pneumococcal pneumoniae (Table 1) [4,21,26,37]. Severe cases are
treated as inpatients and less severe cases are treated as outpatients in the model. As we only
had data on access to outpatient care of pneumonia, we had to make assumptions for the other
types of care. Both interventions represent cost savings from the household perspective. After
UPF of pneumonia treatment takes place, individuals would pay 0% of the treatment costs, the
Table 1. (Continued)
Parameter Value Reference
Gini index 0.3 [5]
Utility function as a function of individual income y y^(1-r) / (1-r) with r = 3 S1 Text and
[15,16,43]
U5D, under-five deaths; NPNM, Non-Peumonia Non-Meningitis; Q = income quintile (1 is poorest; 2
second poorest; 3 middle; 4 second richest; 5 richest)
*Authors’ calculations based on EDHS 2011 [21]
** risk reduction of pneumonia on child deaths
*** the average cost of transportation for last consultation across facilities in 2000 was 14.6 Birr, and this
was converted to 2011 US$.
doi:10.1371/journal.pone.0142691.t001
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government would pay 100% of the treatment costs. After UPF of the vaccine is introduced,
individuals pay 0% of vaccine costs. Vaccine efficacy and their reduction of incidence rates
have an indirect impact on the size of private expenditures. Vaccines reduce private household
expenditures since vaccines lower the risk that a child gets a pneumococcal disorder (and the
OOP expenditures associated with inpatient and outpatient care). In addition, pneumococcal
vaccination indirectly reduces the household risk of experiencing transport costs since pneu-
mococcal disorders are prevented. The baseline cost of transportation to a facility was on aver-
age 14.6 Ethiopian Birr in 2000 [38], which converts to $6.8 in 2011.
We estimate the total incremental cost to the government of increased coverage of each pro-
gram. Vaccine costs are estimated by multiplying the incremental coverage (38% of births)
with average system costs per injection (0.5 US$) [39] and size of co-financing per dose (3.5 US
$ per dose with no GAVI subsidies (base case) and 0.2 US$ per dose with full GAVI subsidies)
[22]. Average system costs per vaccinated child include cold storage, transport, training and
public communication. The GAVI subsidies are actually greater than $3.30 per vial because of
the additional collective US$1.5 billion payments made under the Advanced Market Commit-
ment [40]. Governmental savings of the vaccine program are included by taking into account
effects on reduced treatment demand for pneumococcal disorders (pneumonia, meningitis,
non-pneumonia and non-meningitis). Treatment costs for pneumonia treatment are estimated
by adding: (1) the costs of reducing current OOP expenditures due to pneumonia treatment
from 34% to 0%; and (2) the costs of an incremental scale-up of UPF of pneumonia treatment
by 10 percentage points. Average cost per hospitalized case and outpatient case are from Stack
et al. [41] (Table 1), and lowest estimates are used. Before UPF, the health system finances 66%
of unit costs and patients 34% of unit costs. Estimates by Stack et al. [41] are lower than what
was found in a primary study from Zambia [42], where the cost per out-patient visit for pneu-
monia was $48 and the cost per bed day was $215 (2006 US$).
Financial risk protection and money-metric value of insurance provided
We use an approach described in great detail elsewhere [15,16] and in the supplementary data
(S1 Text). Specifically, we apply a standard utility-based model where risk-averse individuals
value protection from the risk of uncertain rare events. UPF provides FRP benefits to house-
holds or ‘insures’ households by averting the otherwise expected OOP expenditures associated
with pneumonia and pneumococcal disease. FRP benefits of health policies can be measured in
different ways. Direct estimates of the households’ private OOP expenditures averted by the
policy is one FRP metric; another is to estimate the number of cases of poverty averted (i.e.
counting the number of individuals no longer falling under a poverty line because of large
OOP expenditures). Here, we use a money-metric value of insurance provided by UPF as our
FRP metric [15,43], which attempts to quantify ‘insurance risk premiums’. Practically, we first
estimate the individual’s expected income before UPF, depending on disease incidence, treat-
ment utilization and associated costs; then we determine the individual’s ‘certainty equivalent’
by assigning individuals a utility function that specifies their risk aversion, where we estimate
the amount of money the individual is willing to have in order to obtain certainty in the out-
come (e.g. potential OOP expenditures due to disease). Finally, we derive a money-metric
value of insurance (or risk premium) provided by the program by calculating the difference
between the expected value of income and the certainty equivalent [15,43]. The FRP metric is
subsequently aggregated at the societal level by using an income distribution in the population
(with a proxy based on country gross domestic product per capita and Gini coefficient [44]).
We take a health system perspective when estimating the governmental cost of both policies
on the one hand and separately add a household perspective when assessing FRP and private
ECEA of Pneumonia Treatment and Pneumococcal Vaccines in Ethiopia
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household expenditures averted on the other hand. For the vaccine intervention, the time hori-
zon is through the five years of one birth cohort as benefits of vaccination largely occur within
the first five years of life, and an annual cross-sectional time horizon is applied for the total
population under five years of age that receive pneumonia treatment. No discounting is used.
The currency year is 2011 and the consumer price index by each year for Ethiopia is used for
inflation-adjustments [5]. The uncertainty in all the parameters in this analysis is high. We
therefore pursued a one-way sensitivity analysis with 20–30% increase or reduction of base
case values for all the parameters.
S1 Text describes the methods in great detail. All analyses were conducted using the R statis-
tical software (www.r-project-org).
Results
Total government cost for the pneumonia treatment base case is $13.9 million annually; this
includes full public finance for those that currently have access to treatment and a 10% increase
in coverage (Table 2). Total vaccine cost for the base case is $11.5 annually; this includes full
public finance of vaccines at a DPT-3 level and vaccine prices at $3.5 per dose (Table 2). The
annual governmental and health systems savings from vaccines is $820,000, and is mainly due
to the expected decrease in pneumococcal disease treatment demand from vaccine effects. A
strengthened routine immunization program would be crucial for a successful scale-up of
PCV. Introduction cost for strengthening the current routine immunization program in Ethio-
pia is around $23.3 million annually (S1 Table). Maintenance of current coverage and
increased coverage at 90% for all basic vaccines are included in the introduction cost. Summed
up, the expected total cost is around $50 million annually for a comprehensive child health
program in Ethiopia that includes 90% coverage of routine immunization, and base case of
PCV-13 and pneumonia treatment.
Table 2. Total government intervention costs, household expenditures averted, deaths averted, and financial risk protection, for each of the two







Financial risk protection (2011US$
value of insurance)
Pneumococcal conjugate vaccine
DPT3 coverage 11 503 000 578 000 2 960 30 300
10% coverage across
income groups
3 152 000 158 000 810 8 300
80% coverage across
income groups
25 212 000 1 266 000 6 480 66 300
90% coverage across
income groups
28 363 000 1 424 000 7 290 74 600
Antibiotic treatment for pneumonia
Maintaining current
coverage
12 364 000 (no UPF)18 677
000 (UPF)
1 831 000* 0* 197 000*
10% incremental coverage 13 937 000 1 831 000 2 610 197 000
80% coverage across all
income groups
67 306 000 1 831 000 20 890 197 000
90% coverage across all
income groups
74 930 000 1 831 000 23 500 197 000
UPF = Universal Public Finance
* By switching from non-UPF to UPF
doi:10.1371/journal.pone.0142691.t002
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Pneumococcal vaccines at a DPT-3 level would avert 2,960 deaths annually among all chil-
dren less than five years of age (Table 2). The pneumonia treatment base case would avert 2610
under-five deaths. In addition, pneumococcal vaccines are estimated to prevent around 60,000
episodes of pneumococcal related pneumonia annually, where 18,000 of these are severe epi-
sodes. Both programs save more lives among the poorest groups due to higher disease burden
in this population; where between 30 and 40% of all lives saved occur in the poorest quintile
(Fig 2). The pro-poor health benefits stands in contrast to the distribution of household private
expenditures averted (Fig 2) (linked to the heterogeneous nature of treatment seeking behavior
across income groups). We assumed UPF for the program, and this would lead to a decrease in
the financial burden for families. Specifically, reductions in household private expenditures
occur for those that currently have access to care and there is no impact on private expendi-
tures for those with no access. As expected, wealthier people avert more private expenditures
(around 60% of total private expenditures averted from UPF of pneumonia treatment would
be felt in the two richest quintiles).
Fig 2 shows the progressive distribution of aggregated FRP afforded, measured as a money-
metric value of insurance. Both base case programs offer between 50% and 60% of the total
FRP to the poorest quintile. There is a shift in gradients between private expenditures averted
and FRP, where the poorest have in absolute terms the lowest private expenditures averted but
benefit from the highest FRP. The high FRP among the poorest groups is due to the large
expected decline in private expenditures relative to income.
Vaccines and treatment offer an efficient purchase of health benefits, household expendi-
tures averted and financial risk protection. Examining results per dollar expenditure, a budget
constraint of $1 million is introduced (Fig 3). The two dimensions of expected health gains
(deaths averted) and FRP afforded are given for the five income groups. The pneumococcal
vaccine program saves 280 lives and the pneumonia treatment program saves 190 lives per $1
million spent (Fig 3). A large proportion of the budget for pneumonia treatment is targeted to
reduce OOP expenditures for those that are already receiving pneumonia treatment. Both pro-
grams are expected to give FRP of $17,000 per $1 million spent.
UPF of vaccines costs around $40 per year of healthy life and UPF of pneumonia treatment
costs $107 per year of healthy life in our analysis when we apply the assumption that the life of
one child equals 50 years of healthy life.
As expected, the impacts of the two interventions vary according to target coverage
(Table 2). An ambitious policy is estimated to cost around $125 million, prevent around $3
million in private expenditures, avert around 30,000 deaths and to give FRP of close to
Fig 2. Level and distribution of household expenditures averted, health benefits (deaths averted and
severe episodes of pneumococcal pneumoniae averted), and financial risk protection, for scale-up of
pneumococcal vaccination and pneumonia treatment provided by universal public finance in
Ethiopia.
doi:10.1371/journal.pone.0142691.g002
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$300,000 annually, where UPF of all interventions are scaled up to a 90% coverage level. As we
see from Table 2, increased coverage of pneumonia treatment does not prevent or add any
incremental private expenditures or FRP. This is because the scaled-up treatment is offered to
patients that do not utilize services in the first place, and therefore there will be no private
expenditures averted. Variations in other parameters also impact results.
Total vaccine program costs vary according to the size of GAVI subsidies applied in the
analysis (Fig 4). If $1 or $0.2 per dose is applied, total annual cost of the vaccine program is
reduced to $3.8 million and $1.4 million, respectively. The co-financing strategy for vaccine
prices offered by the GAVI Alliance makes vaccines substantially more cost-effective at a coun-
try level. Per $1 million spent, a co-finance of $0.2 per vaccine dose gives a total 2,500 deaths
averted and FRP of $27,000, and a co-finance of $1 per dose gives a total 870 deaths averted
and FRP of $9,400. Notably, variations in the incidence of pneumonia largely influence the
costs of treatment: a 3% increment in incidence of pneumonia increases the annual govern-
ment cost of the pneumonia treatment program by $6 million (Fig 4). The size of the out-of-
pocket copayment has a considerable effect on the expected FRP for both interventions: copay-
ment of 20% reduces FRP by 57% for pneumococcal vaccines and 68% for pneumonia treat-
ment and copayment of 50% gives around a twofold increase in FRP for both interventions
(see Fig 4 and S2–S4 Tables for a full set of results of the sensitivity analysis).
Discussion
This study demonstrates the application of ECEA [15] that enables to measure the size of both
health gains and FRP provided for different wealth groups from scale-up of pneumococcal vac-
cination and pneumonia treatment in Ethiopia. The program gives substantially higher health
benefits and FRP for the poor. These measures are useful starting points for an evidence-based
discussion on health priorities across policies and interventions [17].
The estimated cost-effectiveness of PCV-13 in our study is comparable to findings in other
CEAs. A standard CEA from Kenya found that PCV-10 and PCV-13 is highly cost-effective, at
a cost of 59 US$ per Disability Adjusted Life Year averted (around 2000 US$ per live saved)
Fig 3. Expected health benefits (deaths averted) versus financial risk protection afforded (2011 US$),
per $1,000,000 spent for universal public finance of pneumococcal vaccination and/or pneumonia
treatment scale-up in Ethiopia, where results are shown for 5 income quintiles (I is poorest and V is
richest).
doi:10.1371/journal.pone.0142691.g003
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[45]. Program cost is an important factor for the cost-effectiveness of PCV-13. Introduction of
PCV-13 into the existing routine immunization program in Ethiopia would require a strength-
ening of the existing program. The incremental cost of maintaining current coverage and to
increase coverage to 90% for all basic vaccines was estimated to be around $23.3 million annu-
ally. Since we did not evaluate the expected health benefits from a strengthened routine immu-
nization program, it is not possible to estimate how such increase in introduction costs exactly
influence the total cost-effectiveness ratio of PCV-13. This requires further analysis.
However, the ECEA methodology used here goes beyond conventional CEA. Three addi-
tional elements are key outcomes in this ECEA: (1) direct impact on household private expen-
ditures; (2) financial risk protection; and (3) the distributional impact of health benefits, (1)
and (2). All these dimensions are important equity concerns [46] that we are able to separate
out quantitatively. We found that UPF of pneumococcal vaccines and pneumonia treatment
are pro-poor policies, as there are higher FRP and more deaths averted in the lowest income
groups. Therefore, UPF of pneumonia treatment and pneumococcal vaccines can be efficient
policies in a number of dimensions. Financial risks and health risks are transferred to and
pooled by governments or donors with UPF. The progressive distribution of health benefits
and FRP is relevant for policymakers when setting priorities between pneumococcal vaccines,
pneumonia treatment and other interventions for an essential health care package in Ethiopia.
If efficient purchase of financial protection and health benefits for the poor is of importance,
the findings of this study support that UPF of vaccines and pneumonia treatment should be of
high priority in the essential health care package in Ethiopia. The results show that both
Fig 4. Uncertainty analysis for each of the two policies (universal public finance of pneumonia treatment and pneumococcal vaccines) in Ethiopia,
key variables are modified as a one-way deterministic sensitivity analyses, (for more detailed results across income quintiles see S2–S4 Tables).
doi:10.1371/journal.pone.0142691.g004
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interventions are progressive prioritizations as interventions are most cost-effective in the
poorest groups, which is also confirmed by the high FRP among poor patients per $ invested.
Interestingly, the higher income groups have more private expenditures averted from these
policies since access to healthcare is higher in these groups and UPF will minimize those OOP
expenditures. However, there is less disposable income among the poorest, and this is the main
reason why we observe a shift in the gradient between poor and rich groups when we switch
from private expenditures averted to FRP provided by the program. The lower income groups
have higher health benefits even if the coverage is highest in the richest income groups. The
progressive distribution of health benefits is due to the fact that disease burden is much higher
in low-income groups. We did not test targeting policies of the poor because of the political
and ethical controversies surrounding such policies [47] and the fact that there is limited evi-
dence documenting that targeting actually benefits the poor.
Lower respiratory infections are complex. Children often get infected several times a year,
only a few cases end up as severe infections and multiple pathogens are involved. This com-
plexity should be reflected in disease models. We draw on results from other primary studies to
capture this complexity. However, the observational studies or clinical trials we rely on have
several limitations. One major limitation is that pathogens are rarely identified in the studies
and the distributions of pathogens in Ethiopia are not well known. Case fatality rate and the
effectiveness of PCV-13 and amoxicillin vary between pathogens, and this may alter our find-
ings. Case fatality may also vary across income groups. We assume that pneumococcal deaths
follow the same income gradient as all<5 deaths [19] because we could not identify any epide-
miological studies from Africa that report pneumococcal deaths across income groups. Even if
pneumonia and pneumococcal deaths account for a large proportion of all<5 deaths [26], this
is a limitation of the model. It is important to address the income gradient of pneumococcal
disease burden, as well as other diseases, in future epidemiological studies.
The sensitivity analysis illustrates the substantial impact GAVI subsidies have on health
benefits and FRP (Fig 4). It seems plausible, from an Ethiopian perspective, to apply the subsi-
dized vaccine prices in a policy decision on whether to scale up vaccines or not. Global develop-
ment aid to such subsidies therefore has a tremendous impact on national estimates, and we
see that this yields substantially higher benefits for the poorest groups.
There are limitations of our model. First, we do not have disease-specific data on OOP
expenditures in Ethiopia due to pneumonia and pneumococcal disease. Second, incidence dis-
tribution of various pneumococcal serotypes in Ethiopia is not taken into account and we
assume that PCV-13 targets the most lethal and common serotypes in Ethiopia. There is some
evidence showing that PCV-13 protects against 74%–88% of all invasive pneumococcal sero-
types globally [30]. It has been shown limited variability of protection of PCV-13 across regions
[30], which support the accuracy of PCV-13 for an Ethiopian setting. Third, since this is a static
model, the model cannot take into account the indirect effects on mortality of serotype replace-
ment in the scale-up of PCV-13. However, some evidence question the impact on mortality of
serotype replacement due to lower invasiveness seen by replacing serotypes [48]. Fourth, herd
immunity of PCV-13 was not taken into account. Studies conducted in high-income settings
showed positive indirect benefits to unvaccinated children, but the attributable fraction of herd
immunity on the total mortality reduction from PCV-13 is uncertain and is likely to vary by
setting [31,49]. The inclusion of herd immunity into the model would increase both the health
and financial benefits of the pneumococcal vaccines. Indeed, in spite of requiring larger
amounts of data, there is an important need for economic evaluations using more complex
models such as dynamic compartmental of infectious diseases [50,51] which can capture pat-
terns of social mixing, inter-generational effects and herd immunity more generally. Fifth, the
impact of PCV on FRP and deaths averted may be underestimated as we only include total
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benefits from those that receive all three PCV injections. The potential benefits from the 1st
and 2nd dose are not included as there is limited data on these effects.
Conclusion
The current economic growth in Ethiopia (estimated at 7.5% in 2013 [52]) opens for increasing
domestic investments in public finance of pneumococcal conjugate vaccination and pneumo-
nia treatment for children. Our results indicate that such investments entail a low risk where
there is a high probability that many children will be saved and that these policies can prevent
many families from facing impoverishing health expenditures. UPF of vaccines and treatment
should therefore be made universally available before less cost-effective interventions are intro-
duced into the Ethiopian health system. The ECEA approach captures financial risk protection
and equity into the economic evaluation of vaccine policy, and enables the selection of vaccine
packages based on the efficient purchase of both health and financial risk protection benefits.
With ECEA, investments in vaccine policy could further be analyzed comparatively with policy
investments in other development sectors. Such cross-sectorial analyses are highly relevant for
the Ethiopian Ministry of Development.
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